<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immunemodulating gene expression program active across major cancer types</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Jan</forename><surname>Budczies</surname></persName>
							<email>jan.budczies@charite.de</email>
							<idno type="ORCID">0000-0002-1959-2240</idno>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité -Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Corporate Member of Freie Universität Berlin</orgName>
								<orgName type="institution" key="instit3">Humboldt-Universität zu Berlin</orgName>
								<orgName type="institution" key="instit4">Berlin Institute of Health</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Berlin and Heidelberg partner sites</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité -Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Corporate Member of Freie Universität Berlin</orgName>
								<orgName type="institution" key="instit3">Humboldt-Universität zu Berlin</orgName>
								<orgName type="institution" key="instit4">Berlin Institute of Health</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin and Heidelberg partner sites, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carsten</forename><surname>Denkert</surname></persName>
							<idno type="ORCID">0000-0002-1959-2240</idno>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité -Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Corporate Member of Freie Universität Berlin</orgName>
								<orgName type="institution" key="instit3">Humboldt-Universität zu Berlin</orgName>
								<orgName type="institution" key="instit4">Berlin Institute of Health</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Berlin and Heidelberg partner sites</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution" key="instit1">Charité -Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Corporate Member of Freie Universität Berlin</orgName>
								<orgName type="institution" key="instit3">Humboldt-Universität zu Berlin</orgName>
								<orgName type="institution" key="instit4">Berlin Institute of Health</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin and Heidelberg partner sites, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Balázs</forename><surname>Győrffy</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">MTA TTK Lendulet Cancer Biomarker Research Group</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">2nd Dept. of Pediatrics</orgName>
								<orgName type="institution">Semmelweis University</orgName>
								<address>
									<settlement>Budapest</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Schirmacher</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Berlin and Heidelberg partner sites</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin and Heidelberg partner sites, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Albrecht</forename><surname>Stenzinger</surname></persName>
							<email>albrecht.stenzinger@med.uni-heidelberg.de</email>
							<affiliation key="aff1">
								<orgName type="department">German Cancer Consortium (DKTK)</orgName>
								<address>
									<addrLine>Berlin and Heidelberg partner sites</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">German Cancer Research Center (DKFZ)</orgName>
								<orgName type="institution">German Cancer Consortium (DKTK)</orgName>
								<address>
									<settlement>Berlin and Heidelberg partner sites, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<addrLine>Im Neuenheimer Feld 224</addrLine>
									<postCode>69120</postCode>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immunemodulating gene expression program active across major cancer types</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">3502CD010B1546D65106577114EAA372</idno>
					<idno type="DOI">10.1186/s12920-017-0308-8</idno>
					<note type="submission">Received: 19 June 2017 Accepted: 20 November 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cancer</term>
					<term>Immunotherapy</term>
					<term>PD-L1</term>
					<term>DNA copy number alterations</term>
					<term>Chromosome 9p gain</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Inhibition of the PD-L1/PD-1 immune checkpoint axis represents one of the most promising approaches of immunotherapy for various cancer types.</s><s>However, immune checkpoint inhibition is successful only in subpopulations of patients emphasizing the need for powerful biomarkers that adequately reflect the complex interaction between the tumor and the immune system.</s><s>Recently, recurrent copy number gains (CNG) in chromosome 9p involving PD-L1 were detected in many cancer types including lung cancer, melanoma, bladder cancer, head and neck cancer, cervical cancer, soft tissue sarcoma, prostate cancer, gastric cancer, ovarian cancer, and triple-negative breast cancer.</s><s>Methods: Here, we applied functional genomics to analyze global mRNA expression changes associated with chromosome 9p gains.</s><s>Using the TCGA data set, we identified a list of 75 genes that were strongly up-regulated in tumors with chromosome 9p gains across many cancer types.</s><s>Results: As expected, the gene set was enriched for chromosome 9p and in particular chromosome 9p24 (36 genes and 23 genes).</s><s>Furthermore, we found enrichment of two expression programs derived from genes within and beyond 9p: one implicated in cell cycle regulation (22 genes) and the other implicated in modulation of the immune system (16 genes).</s><s>Among these were specific cytokines and chemokines, e.g.</s><s>CCL4, CCL8, CXCL10, CXCL11, other immunoregulatory genes such as IFN-G and IDO1 as well as highly expressed proliferation-related kinases and genes including PLK1, TTK, MELK and CDC20 that represent potential drug targets.</s><s>Conclusions: Collectively, these data shed light on mechanisms of immune escape and stimulation of proliferation in cancer with PD-L1 CNG and highlight additional vulnerabilities that may be therapeutically exploitable.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Programmed cell death 1 (PD-1)/PD-ligand1 (PD-L1) checkpoint inhibition has emerged as a promising treatment strategy in different advanced and often otherwise untreatable tumors in a growing number of cancer types.</s><s>In this context immunohistochemical (IHC) evaluation of PD-L1 protein expression has been proposed as a biomarker that predicts treatment efficacy.</s><s>However, different IHC-antibody clones used for PD-L1 detection and different evaluation methods including different cutoff values to distinguish 'positive' from 'negative' tumors introduce a substantial variance in the determination of PD-L1 status.</s><s>These ambiguities and the complex interplay of cancercell-inherent, microenvironment-associated and hostrelated factors <ref type="bibr" target="#b0">[1]</ref> advocate further investigation of the underlying biology to identify additional biomarkers that aid current stratification strategies.</s></p><p><s>PD-L1 copy number gains (CNG) are prevalent in significant subsets of different cancers including triple negative breast cancer <ref type="bibr" target="#b1">[2]</ref>, Hodgkin's lymphoma <ref type="bibr" target="#b2">[3]</ref>, cancer of unknown primary <ref type="bibr" target="#b3">[4]</ref>, NSCLC <ref type="bibr" target="#b4">[5]</ref>, SCLC <ref type="bibr" target="#b5">[6]</ref>, and gastric cancer <ref type="bibr" target="#b6">[7]</ref>.</s><s>In particular, Hodgkin's lymphomas harboring PD-L1 CNG were reported to exhibit increased PD-L1 expression and to respond well to immune checkpoint inhibition <ref type="bibr" target="#b2">[3]</ref>.</s><s>Adding to the growing body of evidence, enabled by The Cancer Genome Atlas (TCGA) a recent pan-cancer analysis of almost 10,000 tumors showed that PD-L1 CNG were abundant in many cancer types with both focal and non-focal gains typically occurring at frequencies between 2% and 10% <ref type="bibr" target="#b7">[8]</ref>.</s><s>In this study, we identified a 7.8-Mbp region of 38 genes located in chromosome 9p24 (core amplified region) that is co-amplified with PD-L1 in more than 80% of tumors with focal PD-L1 gains across 22 cancer types.</s><s>The core amplified region includes the genes PD-L1, PD-ligand 2 (PD-L2) and Janus kinase 2 (JAK2).</s><s>Following up on these findings, we here show that chromosome 9p copy number gains are associated with specific mRNA expression changes enriched for genes implicated in cell cycle regulation and immune cell response.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>PD-L1 copy number alteration (GISTIC) and genome-wide mRNA expression data (RNAseq v2) of the following 21 cancer types profiled in the TCGA project were obtained from the cBioPortal <ref type="bibr" target="#b8">[9]</ref>: Bladder Urothelial Carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Colorectal adenocarcinoma (COADREAD), Glioblastoma multiforme (GBM), Head and Neck squamous cell carcinoma (HNSC), Kidney renal clear cell carcinoma (KIRC), Kidney Renal Papillary Cell Carcinoma (KIRP), Brain Lower Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), Pheochromocytoma and Paraganglioma (PCPG), Prostate Adenocarcinoma (PRAD), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD), Papillary Thyroid Carcinoma (THCA), and Uterine Corpus Endometrial Carcinoma (UCEC).</s><s>All TCGA data were freely available without restrictions on their use in publications (https://cancergenome.nih.gov/publications/</s><s>publicationguidelines).</s></p><p><s>PD-L1 copy numbers alterations were evaluated using the calls reported by the TCGA consortium based on Affymetrix SNP 6.0 array data and the GISTIC 2.0 algorithm <ref type="bibr" target="#b9">[10]</ref>.</s><s>PD-L1 status was assessed as "loss" for calls −2 and −1, as "normal" for call 0, and as "gain" for calls 1 and 2. Copy number calls and upper quartile normalized RSEM estimates of mRNA expression were obtained from the cBioPortal (http://www.cbioportal.org).</s><s>Expression values were log2(x + 1) transformed prior to statistical analysis and visualization.</s><s>Differential expression between tumors with and without PD-L1 gains as well as between tumors with and without PD-L1 losses was assessed using Welch's t-test.</s><s>Hierarchical clustering was performed using Pearson correlations as similarity measure and the average linkage method to determine the distance between clusters.</s><s>Non-significant fold changes were set to one before clustering.</s><s>In a genome-wide mRNA expression analysis, a list of 75 strongly and recurrently up-regulated genes was identified by filtering for genes showing significant (p &lt; 0.05) and at least 1.5-fold enhanced mRNA expression in tumors with PD-L1 gains across at least 6 cancer types (Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>).</s><s>The fold change threshold was added to the gene selection criterion to concentrate on strong expression changes that can be potentially therapeutically targeted.</s><s>Pan-cancer significance was assessed by combining the p-values of specific cancer types using Fisher's method.</s><s>Enrichment analysis of functional categories was performed based on gene ontology (GO) annotations obtained from msigdb v5.2 C5 (http:// software.broadinstitute.org/gsea/msigdb)</s><s>with significance assessment by Fisher's exact test (Additional file 2: Table <ref type="table">S2</ref>).</s><s>Among several enriched GO categories that were connected with the biological motives proliferation and immunology the largest of these, 'cell cycle' (GO:0007049) and 'immune system process' (GO:0002376), were utilized for annotation of the 75 genes.</s><s>Statistics and graphics generation were performed using the programming language R. Everywhere, p-values &lt; 0.05 were considered significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Comparing tumors with and without PD-L1 CNG in 22 cancer types, we found significant mRNA expression changes of PD-L1 in 11 cancer types, of PD-L2 in 9 cancer types and of JAK2 in 15 cancer types (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Some of the detected PD-L1 mRNA expression changes were very high such as in lung squamous cell cancer (fold change = 4.9), bladder cancer (fold change = 4.1), head and neck cancer (fold change = 2.9), cervical cancer (fold change = 2.7) and cutaneous melanoma (fold change = 2.2).</s><s>Furthermore, we explored the global mRNA expression pattern of chromosome 9p using hierarchical clustering and heatmap visualization (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>In the 11 cancer types with significant PD-L1 mRNA expression changes, between 124 to 342 genes (15% to 42%) located on chromosome 9p were found to be differentially expressed.</s><s>Comparing tumors with and without PD-L1 loss, we identified 14 cancer types with significant PD-L1 mRNA expression changes and 167 to 415 genes (20% to 51%) with modulated mRNA expression.</s><s>Genes showing frequent up-regulation in tumors with PD-L1 gains included PD-L1, PD-L2, JAK2, and B4GALT1.</s><s>Genes showing frequent down-regulation in tumors with PD-L1 losses included PD-L1, PD-L2 and IFNB1.</s></p><p><s>Taking a more comprehensive approach, we analyzed the setting 'chromosome 9p gain' in a genome-wide context and identified 75 top genes that were strongly and recurrently up-regulated (Fig. <ref type="figure">2</ref> and Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>).</s><s>In a pan-cancer analysis and after Bonferroni correction for 22,849 genes, 74 of these were significantly associated with 9p gain status.</s><s>While 36 strongly up-regulated genes (48%) were located on chromosome 9p (including PD-L1, PD-L2 and JAK2), the remaining 39 genes (52%) were located in other genomic regions.</s><s>In particular, 21 genes were located in the core amplified region in chromosome 9p24 that we described in <ref type="bibr" target="#b7">[8]</ref>.</s><s>Twenty-two strongly up-regulated genes belonged to the GO category 'cell cycle' (ASPM, CDC20, CDCA8, CDKN2A, CENPA, CENPF, CENPI, CLSPN, FAM83D, GTSE1, HAUS6, IFNG, KIF18B, KIF2C, MELK, MYBL2, NUF2, PLK1, SPC24, TPX2, TTK, UHRF2).</s><s>The vast majority of these genes play a role in the coordinated regulation of microtubule assembly and chromosomal segregation during mitosis.</s><s>Sixteen strongly up-regulated genes belonged to the GO category 'immune system process' (ADAMDEC1, APLN, CCL4, CCL8, CXCL10, CXCL11, FCGR3A, GBP5, IDO1, IFI44L, IFNG, JAK2, KIF2C, MELK, PD-L1, PD-L2).</s><s>Most of these genes encode cytokines and chemokines but also link immune response with tumor metabolism, such as IDO1 encoding indoleamine-2,3-dioxygenase 1. Enrichment of the both GO categories was highly significant (cell cycle: p = 2.5E-10, immune system process: p = 0.00096).</s><s>Interestingly, as shown in Fig. <ref type="figure">2</ref>, upregulation of immune system-related genes was particularly enriched in prostate adenocarcinoma, breast cancer, cervical cancer,  Genes belonging to recurrently amplified or deleted regions (as identified in <ref type="bibr" target="#b7">[8]</ref>) are marked by a star squamous cell lung cancer, head and neck cancer and bladder cancer, while genes regulating cellular proliferation were strongly expressed in glioma, papillary renal cell carcinoma and uterine corpus endometrial carcinoma well as in breast cancer, prostate cancer, sarcomas, and glioblastomas.</s><s>Higher expression levels of genes on 9p were observed across most cancer types except for papillary thyroid carcinoma as well as pheochromocytoma and paraganglioma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Functional genomics analysis of PD-L1 CNG tumors revealed strong and recurrent mRNA expression changes of genes within and outside chromosome 9p.</s><s>Before, we showed that approximately half of the PD-L1 CNGs in the major cancer types occur together with amplification of chromosome 9p or the entire chromosome 9 (non-focal gains), while the other half of PD-L1 CNGs frequently cooccurs with gain of a 38-gene core amplified region located in chromosome 9p24 (focal gains) <ref type="bibr" target="#b7">[8]</ref>.</s><s>Here were analyzed focal and non-focal CNGs together and identified 75 genes (21 in located the core amplified region) that were strongly and recurrently up-regulated in PD-L1 CNG tumors.</s><s>The gene set was enriched for the biological motives 'cell cycle' and 'immune system process' and included known drivers of tumor growth and drug targets.</s></p><p><s>A recent study showed that PD-L1 CNG is a powerful predictive biomarker in patients with relapsed or refractory Hodgkin lymphoma who were treated with nivolumab <ref type="bibr" target="#b2">[3]</ref>.</s><s>In keeping with these data, we recently demonstrated that PD-L1 amplification accompanied by overexpression can also be used to identify patients with solid tumors who benefit from PD-1 blockade <ref type="bibr" target="#b3">[4]</ref>.</s><s>These data support a view that PD-L1 CNGs could help to predict response to checkpoint inhibitors in solid tumors.</s><s>Testing for PD-L1 amplifications could be easily implemented in a routine setting using in situ hybridization based assays such as FISH or using targeted DNA sequencing <ref type="bibr" target="#b10">[11]</ref>.</s><s>However, prospective clinical trials and retrospective-prospective analyses of existing clinical trial tissue cohorts are warranted to get a comprehensive picture on the clinical utility of PD-L1 CNGs in solid cancer types.</s></p><p><s>Copy number and gene expression analyses uncovered additional potential drug targets, such as amplified and overexpressed JAK2 (Table <ref type="table" target="#tab_0">1</ref>), which has been implicated in the regulation of PD-L1 expression <ref type="bibr" target="#b11">[12]</ref> and appears to play a role in tumor growth and resistance to Fig. <ref type="figure">2</ref> Heatmap of the top list of 75 strongly and recurrent differentially expressed genes (as defined in methods) between tumors with and without PD-L1 CNGs.</s><s>Significant (p &lt; 0.05) changes are highlighted as colored boxes.</s><s>The genes are annotated to the following three groups: A = gene located on chromosome 9p, B = gene plays a role in cell cycle regulation, C = gene is implicated in immune system processes chemotherapy <ref type="bibr" target="#b12">[13]</ref>.</s><s>B4GALT1 encoding β-1, 4-Galactosyltransferase is also frequently co-amplified and overexpressed, and has been demonstrated to mediate multidrug resistance in leukemia cell lines <ref type="bibr" target="#b13">[14]</ref>.</s><s>PD-L2, the gene next to PD-L2 located about 40 kbp toward the centromere, has been demonstrated to be always coamplified and co-deleted with PD-L1 across major cancer types <ref type="bibr" target="#b7">[8]</ref>.</s><s>Consistent with this result, we here found the two genes to be co-regulated on transcriptional level in many cancer types.</s><s>PD-L2 is a second ligand for PD-L1 inhibiting T cell activation <ref type="bibr" target="#b14">[15]</ref> and has recently been demonstrated to be associcated with clinical outcome in head and neck cancer independent of PD-L1 <ref type="bibr" target="#b15">[16]</ref>.</s></p><p><s>Taking a broader view, our analysis identified two gene expression programs that were significantly associated with cancers harboring 9p gains: regulation of cell cycle and proliferation as well as modulating and fine tuning of immune cell response.</s><s>As expected, the latter comprised PD-L1, PD-L2, and JAK2 already discussed above.</s><s>Additionally, however, we noted a specific set of genes encoding chemokines and cytokines, namely CCL4, CCL8, CXCL10, CXCL11, IFI44L, IDO1, and IFNG that were upregulated in 9p CNG cancers.</s><s>Chemokines and cytokines are well known to guide macrophages, and T-cells including CD8-positive T-lymphocytes to the tumor microenvironment and are associated with outcome <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b17">18]</ref>.</s><s>As the RNA-seq data analyzed here were derived from the entire tumor including its stromal and inflammatory components we were unable to discern whether upregulated expression levels stem directly from tumor cells or adjacent stromal cells.</s><s>However, these data indicate that cancers with 9p gains involving PD-L1 are associated with a 'hot microenvironment' attracting effector cells of the immune system that could eliminate tumor cells as soon as checkpoint blockade is in place and counteracts the anergic state.</s><s>On the other hand, chemokines are known to play a role in metastatic spread of tumor cells as they may express CC and CXC chemokine receptors <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref>.</s><s>Together with PD-L1 CNG that hamper successful immune attack due to increased PD-L1 protein levels, chemokine secretion could drive tumor survival by supporting local or distant spread.</s><s>Similarly, while IFNG exerts clear antitumorigenic functions it appears to be also implicated in tumor progression in some settings <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>Interestingly, among the upregulated genes IDO1 encoding indoleamine-2,3-dioxygenase 1 was identified.</s><s>This enzyme, whose expression can be induced by IFNG <ref type="bibr" target="#b23">[24]</ref>, is centrally involved in the degradation of tryptophan in tumor cells whose depletion eventually results in cell cycle arrest and apoptosis of T-cells <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref>, thus possibly supporting PD-L1 CNG tumors to escape immune surveillance.</s><s>Conversely, this IDO1-mediated mechanism of immune suppression can be exploited therapeutically by inhibition of the catalytic activity of IDO1 <ref type="bibr" target="#b28">[29]</ref> suggesting that dual inhibition of both PD-1 and IDO1 could be a promising approach to enhance efficacy of checkpoint blockade.</s><s>Several studies investigating dual IDO1-PD1 blockade in solid tumor types are underway and preliminary results are encouraging <ref type="bibr" target="#b29">[30,</ref><ref type="bibr" target="#b30">31]</ref>.</s></p><p><s>The second expression program that we identified in cancers with 9p gains includes genes involved in formation of microtubules, chromosome segregation and governing mitosis.</s><s>For example, CDC20 encoding cell-division cycle protein 20 homologue plays a role in chromosome separation and transition to G1 phase after mitosis, and may be a suitable drug target <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s>Similarly PLK1, which is well known to control metaphase to anaphase transition and mitotic exit, is upregulated in these cancers and pre-clinical as well as clinical data collectively suggest that PLK1 inhibition can be a promising strategy in cancer therapy <ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref>.</s><s>Recently, overexpression of TTK, another checkpoint in mitosis <ref type="bibr" target="#b36">[37]</ref>, was reported to occur in triple negative breast cancers <ref type="bibr" target="#b37">[38]</ref>, which frequently harbor PD-L1 amplifications <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>In line with this finding, our analysis showed upregulation of TTK across many cancers that harbor CNG of 9p involving PD-L1.</s><s>MELK encoding maternal embryonic leucine zipper kinase appears to play a role in governing proliferation and conferring anti-apoptotic properties to tumor cells.</s><s>With the recent development of inhibitors <ref type="bibr" target="#b38">[39]</ref>, additional MELK inhibition may also be a therapeutic option in patients with PD-L1 amplified cancers <ref type="bibr" target="#b39">[40]</ref>.</s></p><p><s>On a genome-wide scale, recurrent patterns of copy number alterations have been discovered across patients and cancer types suggesting their shaping by selective pressures and roles in tumor genesis and tumor growth <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b41">42]</ref>.</s><s>However, the effects of these, in particular of small gene dosage alterations including chromosome or chromosome arm gains or losses, on the phenotypic level are incompletely understood.</s><s>In a recent pan-cancer analysis, a copy number alteration signature has been linked up-regulation of glycolysis <ref type="bibr" target="#b42">[43]</ref>, while chromosome 8p loss in breast cancer has been linked to alterations in lipid metabolism <ref type="bibr" target="#b43">[44]</ref>.</s><s>Here, we demonstrated a link of 9p gains to the regulation of proliferation and immune response.</s><s>Our observations support a view of copy number alterations as hard-wired genetic changes that maintain cancer hallmarks including 'self-sufficiency in growth' and 'evasion from the immune system' from Hanahan's and Weinberg's list <ref type="bibr" target="#b44">[45]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In summary, we identified a gene signature that is upregulated in PD-L1 CNG tumors across many cancer types.</s><s>The data contribute to understanding the biology of these cancers and highlight additional vulnerabilities that might be</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Shaping of mRNA expression of chromosome 9p by copy number alterations in chromosome 9p including PD-L1. a Heatmap showing mRNA fold changes tumors with and without PD-L1 gain.</s><s>b Heatmap showing mRNA fold changes of tumors with and without PD-L1 loss.</s><s>Significant (p &lt; 0.05) changes are highlighted as colored boxes.</s><s>Genes belonging to recurrently amplified or deleted regions (as identified in [8]) are marked by a star</s></p></div></figDesc><graphic coords="4,101.99,94.85,391.36,594.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,127.28,94.85,340.76,293.10" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Analysis of differential mRNA expression of PD-L1, PD-L2 and JAK2 in tumors with PD-L1 CNG compared to tumors without PD-L1 CNG</s></p></div></figDesc><table><row><cell>Cancer</cell><cell>PD-L1</cell><cell></cell><cell>PD-L2</cell><cell></cell><cell>JAK2</cell><cell></cell></row><row><cell>type</cell><cell>fold change</cell><cell>p</cell><cell>fold change</cell><cell>p</cell><cell>fold change</cell><cell>p</cell></row><row><cell>Lusc</cell><cell>4.9</cell><cell>1.60E-27</cell><cell>2.3</cell><cell>3.80E-13</cell><cell>1.8</cell><cell>3.70E-14</cell></row><row><cell>Blca</cell><cell>4.1</cell><cell>7.70E-14</cell><cell>2.6</cell><cell>2.80E-06</cell><cell>2</cell><cell>3.60E-14</cell></row><row><cell>Hnsc</cell><cell>2.9</cell><cell>1.30E-16</cell><cell>2.5</cell><cell>1.20E-14</cell><cell>2.1</cell><cell>7.10E-19</cell></row><row><cell>cesc</cell><cell>2.7</cell><cell>2.50E-08</cell><cell>2</cell><cell>9.00E-05</cell><cell>1.9</cell><cell>4.90E-07</cell></row><row><cell>skcm</cell><cell>2.2</cell><cell>0.0073</cell><cell>1.5</cell><cell>0.12</cell><cell>2</cell><cell>0.00026</cell></row><row><cell>paad</cell><cell>2</cell><cell>0.14</cell><cell>1.6</cell><cell>0.5</cell><cell>1.3</cell><cell>0.23</cell></row><row><cell>sarc</cell><cell>1.9</cell><cell>0.0028</cell><cell>2.2</cell><cell>0.00013</cell><cell>1.4</cell><cell>0.00042</cell></row><row><cell>luad</cell><cell>1.8</cell><cell>0.00078</cell><cell>1.2</cell><cell>0.12</cell><cell>1.4</cell><cell>7.60E-05</cell></row><row><cell>prad</cell><cell>1.8</cell><cell>9.00E-04</cell><cell>1.6</cell><cell>0.002</cell><cell>1.4</cell><cell>0.00017</cell></row><row><cell>stad</cell><cell>1.8</cell><cell>0.0026</cell><cell>1</cell><cell>0.79</cell><cell>1.4</cell><cell>0.0061</cell></row><row><cell>kirc</cell><cell>1.7</cell><cell>0.18</cell><cell>1</cell><cell>0.98</cell><cell>1.2</cell><cell>0.15</cell></row><row><cell>ov</cell><cell>1.7</cell><cell>5.20E-07</cell><cell>1.3</cell><cell>0.034</cell><cell>1.6</cell><cell>4.40E-12</cell></row><row><cell>kirp</cell><cell>1.6</cell><cell>0.44</cell><cell>1.1</cell><cell>0.87</cell><cell>1.3</cell><cell>0.45</cell></row><row><cell>thca</cell><cell>1.5</cell><cell>0.45</cell><cell>1.4</cell><cell>0.3</cell><cell>1.2</cell><cell>0.4</cell></row><row><cell>gbm</cell><cell>1.4</cell><cell>0.34</cell><cell>1.6</cell><cell>0.1</cell><cell>1.3</cell><cell>0.014</cell></row><row><cell>ucec</cell><cell>1.4</cell><cell>0.17</cell><cell>1.2</cell><cell>0.51</cell><cell>1.2</cell><cell>0.28</cell></row><row><cell>brca</cell><cell>1.3</cell><cell>0.016</cell><cell>1.3</cell><cell>0.002</cell><cell>1.3</cell><cell>2.40E-05</cell></row><row><cell>lihc</cell><cell>1.2</cell><cell>0.52</cell><cell>-1</cell><cell>0.91</cell><cell>1.5</cell><cell>0.0083</cell></row><row><cell>coadread</cell><cell>1.1</cell><cell>0.62</cell><cell>1.1</cell><cell>0.59</cell><cell>1.3</cell><cell>0.00038</cell></row><row><cell>lgg</cell><cell>-1</cell><cell>0.88</cell><cell>2.5</cell><cell>0.004</cell><cell>1.4</cell><cell>0.00027</cell></row><row><cell>pcpg</cell><cell>−2.6</cell><cell>0.27</cell><cell>−1.3</cell><cell>0.13</cell><cell>−1.2</cell><cell>0.48</cell></row></table><note><p><s>Significant changes (p &lt; 0.05) are highlighted Investigated cancer types: Bladder Urothelial Carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Colorectal adenocarcinoma (COADREAD), Glioblastoma multiforme (GBM), Head and Neck squamous cell carcinoma (HNSC), Kidney renal clear cell carcinoma (KIRC), Kidney Renal Papillary Cell Carcinoma (KIRP), Brain Lower Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), Pheochromocytoma and Paraganglioma (PCPG), Prostate Adenocarcinoma (PRAD), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD), Papillary Thyroid Carcinoma (THCA), and Uterine Corpus Endometrial Carcinoma (UCEC) Bold data indicate significance (p &lt; 0.05)</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>Not applicable.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>therapeutically exploitable thus possibly sustaining or enhancing efficacy of checkpoint blockers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Additional file 1: Table <ref type="table">S1</ref>.</s><s>Gene list of 75 top up-regulated genes identified in a genome-wide transcriptome analysis across 22 cancer types.</s><s>The list was obtained by filtering for genes harboring significant and at least 1.5-fold enhanced mRNA expression in tumors with PD-L1 gains across at least 6 cancer types.</s><s>Pan-cancer p-values were calculated using Fisher's method (* = significant, ** = significant after Bonferroni correction for 22,849 genes).</s><s>The set of 75 genes was enriched for the chromosomal regions 9p13 to 9p24 (36 genes) as well as the biological processes 'cell cycle' (22 genes) and 'immune system process' (16 genes).</s><s>(XLSX 34 kb)</s></p><p><s>Additional file 2: Table <ref type="table">S2</ref>.</s><s>Enrichment analysis of GO categories in the 75-gene list.</s><s>(XLSX 240 kb) Abbreviations CNG: Copy number gain; JAK2: Janus kinase 2; PD − 1: Programmed cell death protein 1 (PDCD1); PD-L1: Programmed cell death 1 ligand 1 (CD274); PD-L2: Programmed cell death 1 ligand 2 (PDCD1LG2); TCGA: The Cancer Genome Atlas Funding This work was funded by the German Cancer Aid within the TransLUMINAL-B project (to JB and CD), by the German Cancer Consortium (DKTK; to JB, CD, PS, and AS), and by the NVKP_16-1-2016-0037 grant of the National Research, Development and Innovation Office, Hungary (to BG).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p><s>The data analyzed in this study are publicly available from the cBioPortal (http://www.cbioportal.org).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authors' contributions</head><p><s>JB and AS designed the study, CD contributed to the study design.</s><s>JB analyzed data and generated Figures and Tables.</s><s>All authors contributed to the discussion.</s><s>All authors read and approved the final version of the manuscript.</s></p><p><s>Ethics approval and consent to participate Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p><s>Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p><s>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vetizou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Daillere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Roberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamazaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Routy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lepage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Boneca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chamaillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kroemer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1255" to="1269" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Barrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lenkiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Andreozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Cunliffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Klassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Dueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Mccullough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Ramanathan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page" from="26483" to="26493" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&apos;s lymphoma</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ansell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lesokhin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Borrello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Halwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Schuster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Millenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cattry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Freeman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="311" to="319" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud</title>
		<author>
			<persName><forename type="first">S</forename><surname>Groschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bommer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Budczies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bonekamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heining</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Horak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frohlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uhrig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hubschmann</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">1180</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">PD-L1 is Upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Okano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Umemoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tagawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Morodomi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kohno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shimamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kitahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Suzuki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Thorac Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="62" to="71" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Genomic amplification of CD274 (PD-L1) in small-cell lung cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tsuta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Iwakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shiraishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Scheel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uchida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Noguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1220" to="1226" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">N: comprehensive molecular characterization of gastric adenocarcinoma</title>
	</analytic>
	<monogr>
		<title level="j">Cancer Genome Atlas Research</title>
		<imprint>
			<biblScope unit="volume">513</biblScope>
			<biblScope unit="issue">7517</biblScope>
			<biblScope unit="page" from="202" to="209" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Nature</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Pan-Cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) -associations with gene expression, mutational load, and survival</title>
		<author>
			<persName><forename type="first">J</forename><surname>Budczies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bockmayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Denkert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Klauschen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Groschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Darb-Esfahani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pfarr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leichsenring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Onozato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Lennerz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="626" to="639" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cerami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Dogrusoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Gross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Sumer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Aksoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jacobsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Heuer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Larsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="401" to="404" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mermel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Meyerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Beroukhim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Getz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Biol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">R41</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Budczies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pfarr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stenzinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Treue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Endris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ismaeel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bangemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Blohmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dietel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="13236" to="13247" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bellucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bommarito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ritz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncoimmunology</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">e1008824</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Balko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Schwarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Estrada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Giltnane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Davila-Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Dean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Combs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">334</biblScope>
			<biblScope unit="page" from="334" to="353" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">D</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e654</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">PD-L2 is a second ligand for PD-1 and inhibits T cell activation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Latchman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chernova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chaudhary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Borde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Chernova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Iwai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nunes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="261" to="268" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Yearley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Juco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lunceford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lqm</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Seiwert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3158" to="3167" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Cancer and the chemokine network</title>
		<author>
			<persName><forename type="first">F</forename><surname>Balkwill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="540" to="550" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures</title>
		<author>
			<persName><forename type="first">J</forename><surname>Galon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Angell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bedognetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Marincola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="11" to="26" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A CCL8 gradient drives breast cancer cell dissemination</title>
		<author>
			<persName><forename type="first">E</forename><surname>Farmaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Chatzistamou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kaza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kiaris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">49</biblScope>
			<biblScope unit="page" from="6309" to="6318" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Barbai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Fejos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Puskas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Timar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Raso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="29111" to="29128" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">The emerging role of CXCL10 in cancer (Review)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Stiles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="583" to="589" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The roles of IFN gamma in protection against tumor development and cancer immunoediting</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Old</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Schreiber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="95" to="109" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The two faces of interferon-gamma in cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Zaidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Merlino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="6118" to="6124" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">IFN-gamma is the inducer of indoleamine 2,3-dioxygenase in allografted tumor cells undergoing rejection</title>
		<author>
			<persName><forename type="first">O</forename><surname>Takikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Habara-Ohkubo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yoshida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1246" to="1250" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Duhadaway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Donover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sutanto-Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Prendergast</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="312" to="319" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Munn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mellor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1147" to="1154" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Van den Eynde BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</title>
		<author>
			<persName><forename type="first">C</forename><surname>Uyttenhove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pilotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Theate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Stroobant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Colau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Parmentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Boon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1269" to="1274" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Platten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Doeberitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Oezen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ochs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">673</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Molecular pathways: targeting IDO1 and other tryptophan Dioxygenases for cancer immunotherapy</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spranger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gritsina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Lauing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Wainwright</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="5427" to="5433" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Combination immunotherapy: a road map</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Hodi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Kaufman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Wigginton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunother Cancer</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">16</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Epacadostat Shows Value in Two SCCHN Trials</title>
		<ptr target="https://www.ncbi.nlm.nih.gov/pubmed/28760910" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">F2</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Cdc20: at the crossroads between chromosome segregation and mitotic exit</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kapanidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Bolanos-Garcia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Biochem Sci</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="193" to="205" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">CDC20, a potential cancer therapeutic target, is negatively regulated by p53</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kidokoro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tanikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Katagiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Matsuda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1562" to="1571" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Targeting polo-like kinase 1 for cancer therapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Strebhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ullrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="321" to="330" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Polo-like kinases and oncogenesis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Eckerdt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Strebhardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="267" to="276" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Current clinical trials with polo-like kinase 1 inhibitors in solid tumors</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anti-Cancer Drugs</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="999" to="1006" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells</title>
		<author>
			<persName><forename type="first">J</forename><surname>Daniel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coulter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wilsbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gabrielson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="5384" to="5389" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">V</forename><surname>Maire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baldeyron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vincent-Salomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gravier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Marty-Prouvost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Koning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rigaill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dumont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">e63712</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kudo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fujisawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Taira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Takamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miyamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakamura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="18171" to="18182" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Jubb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kljavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Frantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koeppen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="9751" to="9761" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">The landscape of somatic copynumber alteration across human cancers</title>
		<author>
			<persName><forename type="first">R</forename><surname>Beroukhim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mermel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Raychaudhuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Donovan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barretina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Boehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dobson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Urashima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="issue">7283</biblScope>
			<biblScope unit="page" from="899" to="905" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Pan-Cancer patterns of somatic copy number alteration</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">I</forename><surname>Zack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Cherniack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Saksena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tabak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Z</forename><surname>Zhsng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Mermel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1134" to="1140" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Minasyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lomova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Balanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Delgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Go</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Syst Biol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">914</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crowther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pastor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abbasi</forename><surname>Asbagh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baietti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Troyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Talebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Renzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dehairs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="751" to="766" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Hallmarks of cancer: the next generation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hanahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weinberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="646" to="674" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
